Radiopharm Theranostics prices $4.05 million ADS offering, adds ATM facility

Radiopharm Theranostics Limited, an Australian company, filed a prospectus supplement dated July 23, 2026 for the sale of 384,493,800 ordinary shares, as represented by 1,281,646 American Depositary Shares, to certain institutional investors.¹ Each ADS represents 300 ordinary shares.¹

The offering priced at $3.16 per ADS, for total gross proceeds of $4,050,001.36, with placement agent fees of $283,500.10 and proceeds to the company, before expenses, of $3,766,501.26.¹ The company retained H.C. Wainwright & Co., LLC as exclusive placement agent.¹ Delivery of the ADSs was expected on or about July 28, 2026, subject to customary closing conditions.¹

In a concurrent private placement, Radiopharm is also issuing warrants to purchase up to 1,281,646 ADSs, exercisable at $3.79 per ADS beginning on or after shareholder approval, expiring July 31, 2029.¹

Separately, the company also filed Amendment No. 1, dated July 23, 2026, to a prospectus supplement originally dated December 23, 2025, covering up to $9,300,000 of ADSs to be sold under a sales agreement with Leerink Partners LLC, entered into December 16, 2025, allowing sales from time to time through Leerink Partners acting as sales agent or principal.² Sales under this arrangement may be made as an "at the market" offering under Rule 415(a)(4).² Leerink Partners will earn a commission of 3.0% of the gross sales price per ADS sold.²

The company estimated net proceeds from the institutional offering at approximately $3.3 million, intended to fund preparation for the RAD101 registrational Phase 3 study, completion of RAD 204 dose escalation, and progress on RAD 202, RAD 402 and RV01 programs, along with partnering initiatives and general corporate purposes.¹ The last reported Nasdaq sale price for the ADSs on July 21, 2026 was $4.29 per ADS.²